Optimi Health Corp Dossier - Source-backed chat

Optimi Health Corp

OPTHNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.39

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.64Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $26.6M

Shares Outstanding 5.7M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Optimi Health Corp. (NASDAQ: OPTH) represents a unique, commercial-stage specialty CDMO and pharmaceutical manufacturer in the psychedelic medicine sector. Unlike its peers who operate as drug developers burning massive capital on clinical trials, Optimi is vertically integrated with a Health Canada Drug Establishment Licence (DEL) and GMP-compliant facilities. It is actively generating revenue by supplying finished-dose psilocybin and MDMA capsules directly to clinics in Australia under the TGA Authorized Prescriber Scheme and exporting to clinical trials globally. Following its successful May 2026 Nasdaq uplisting and US$15 million capital raise, the company has secured a robust balance sheet to scale production and fund market entry into the U.S. and Israel.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

Regulatory delays in the U.S. and other target jurisdictions stall market expansion. The company's high cash burn rate and historical reliance on dilutive equity financing persist, leading to further share dilution or liquidity constraints if commercial revenues do not scale fast enough to offset operating losses.

Base CaseCentral scenario

$15.0050%

Optimi steadily expands its clinic network in Australia and continues to secure international export contracts (such as its recent UK Phase 2 trial shipment). The US$15 million Nasdaq funding provides at least 12 to 24 months of operational runway, allowing the company to transition toward self-sustaining commercial operations while preparing for U.S. market entry.

Bull CaseUpside scenario

$15.7530%

Rapid scaling of the Australian market under the newly expanded TGA framework, combined with accelerated FDA approvals in the U.S. following favorable executive orders, drives exponential demand for GMP-grade psilocybin, MDMA, and ibogaine. Optimi successfully captures a dominant share of the global research and special-access supply market, achieving profitability ahead of schedule.

Scenarios reflect our research view at the research date.

Key Investment Merits

Commercial-stage revenue generation with active international supply operations in Australia and Canada.
Fully vertically integrated GMP-certified manufacturing facility in British Columbia with a Health Canada Drug Establishment Licence.
Strong balance sheet following the US$15 million (CAD$18.4 million net) Nasdaq public offering in May 2026.
First-mover advantage in supplying regulated access pathways directly to clinics without middlemen.

Key Investment Risks

High historical operating losses and ongoing cash burn rate.
Heavy dependence on evolving and highly restrictive international regulatory frameworks for controlled substances.
Lack of patent protection for naturally derived botanical psilocybin and standard MDMA formulations.

Thesis Invalidation Triggers

A severe regulatory crackdown or reversal of the Authorized Prescriber Scheme in Australia.
Failure to secure additional export permits or clinical trial supply contracts over the next 12 months.
Rapid depletion of the Nasdaq offering proceeds without a corresponding scale-up in commercial revenues.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.